Search PubMed⌕ Search

Biomedical subjects

B A Lycka

Publications and source records attributed to B A Lycka.

7 recordsLinked to original sources
PubMed1992

EMLA. A new and effective topical anesthetic.

A eutectic mixture of local anesthetics (EMLA) contains 2.5% lidocaine and 2.5% prilocaine in an oil and water emulsion and has been found to give effective, safe analgesia on normal and diseased skin, making it useful for numerous medical and surgical procedures, such as anesthesia for superficial surgery, split-thickness skin grafts, venipuncture, argon laser treatment, epilation, and debridement of infected ulcers. Other indications have included use in postherpetic neuralgia, hyperhidrosis, painful ulcers, and inhibition of itching and burning. To be effective, EMLA should ideally be applied to the desired area for at least 1 hour under an occlusive dressing. The medication has been approved since May 1991 in Canada for use on intact skin and has been available in Europe for many years. This study discusses the background, efficacy, and current and potential uses of EMLA.

Administration, Cutaneous↗
PubMed1990

Meta-analysis for dermatologists.

Meta-analysis is a relatively new statistical technique that is attracting a great deal of attention in the medical and social science literature. This technique is discussed in terms of its tenants, advantages, rudiments, and controversies.

Dermatology↗
PubMed1990

Postherpetic neuralgia and systemic corticosteroid therapy. Efficacy and safety.

Corticosteroids are frequently advocated for use in prevention of postherpetic neuralgia (PHN), although their use is replete with controversy. The present study is a meta-analysis of the four well-controlled clinical studies conducted on this issue. The results indicated there is a statistically significant decrease in proportions affected at 6 and 12 weeks. Standard difference scores were -2.0559 and -4.1442, respectively, and 95% confidence intervals were -3.98% to -31.80% and -14.16% to -43.84%, respectively. At 24 weeks, no differences were detectable between placebo- and corticosteroid-treated groups (SD = 0.6603, p greater than 0.05, 95% confidence intervals of -6.78% to 24.67%). Side effects of treatment were rare and mild, affecting only 2.5% of patients treated with corticosteroids. No patients had dissemination of disease. Systemic corticosteroid treatment decreases the proportion of patients affected by PHN, especially when it is defined as pain occurring at 6 or 12 weeks after the acute event.

Acute Disease↗
PubMed1989

Bowen's disease and internal malignancy. A meta-analysis.

Bowen's disease frequently has been reported to be associated with internal malignancy, although this association has been extremely controversial. The present study uses the technique of meta-analysis to address this issue by pooling the results of the 12 studies published in the English-language literature that previously have attempted to study this issue. The results indicated no significant association between the two conditions (chi square, 1 d.f., = 0.128, p greater than 0.05, 95% confidence interval = 0.105-0.1503). Clearly, no extensive investigation in patients having Bowen's disease is warranted.

Bowen's Disease↗